Brexit Stakes Rise As New UK Prime Minister Takes Over
The UK has a new prime minister in Boris Johnson, who is likely to surround himself with strongly pro-Brexit ministers. The life sciences industry will need to continue lobbying for its interests to be protected in the event of a no-deal exit.
You may also be interested in...
The life sciences industry has given a cautious welcome to the prime minister’s promises that the sector will be a priority once the UK leaves the EU, but has urged the new UK government to take steps to protect medicine supply chains in the event of a no-deal Brexit.
Some changes have been made to UK legislation that will aim to ensure the effective operation of the regulatory system once the country leaves the EU. Areas affected include the QPPV, pediatric and orphan medicines, and the reference product for generic approvals.
The provision of “express” freight capacity for medicines that need to be delivered urgently is among the latest proposals from the UK government to help cope with supply disruptions in the event of a no-deal Brexit. But the biopharmaceutical industry says some of the proposals are too short notice and will place additional burdens on companies.